{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:11:23Z","timestamp":1792098683873,"version":"4.4.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,5]]},"DOI":"10.4103\/0366-6999.192779","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T03:54:43Z","timestamp":1477281283000},"page":"2610-2616","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of the 1-year Outcomes of Conbercept Therapy between Two Different Angiographic Subtypes of Polypoidal Choroidal Vasculopathy"],"prefix":"10.1097","volume":"129","author":[{"given":"Yong","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210129","first-page":"1","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV).1990","volume":"32","author":"Yannuzzi","year":"2012","journal-title":"Retina"},{"key":"R2-15-20210129","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00006324-200407000-00009","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV) presenting with simultaneous choroidal neovascular membrane (CNM)","volume":"81","author":"Shechtman","year":"2004","journal-title":"Optom Vis Sci"},{"key":"R3-15-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1023\/A:1002102630242","article-title":"Optical coherence tomography (OCT) in idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"97","author":"Giovannini","year":"1999","journal-title":"Doc Ophthalmol"},{"key":"R4-15-20210129","first-page":"359","article-title":"Polypoidal choroidal vasculopathy: An update on therapeutic approaches","volume":"8","author":"Wong","year":"2013","journal-title":"J Ophthalmic Vis Res"},{"key":"R5-15-20210129","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","article-title":"Polypoidal choroidal vasculopathy: Incidence, demographic features, and clinical characteristics","volume":"121","author":"Sho","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R6-15-20210129","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","article-title":"Clinical characteristics of exudative age-related macular degeneration in Japanese patients","volume":"144","author":"Maruko","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R7-15-20210129","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/bjophthalmol-2013-303739","article-title":"Changes in fundus autofluorescence after treatments for polypoidal choroidal vasculopathy","volume":"98","author":"Yamagishi","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R8-15-20210129","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/ICU.0b013e3282fb7c33","article-title":"Polypoidal choroidal vasculopathy and treatments","volume":"19","author":"Gomi","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"key":"R9-15-20210129","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/112067210601600506","article-title":"Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy","volume":"16","author":"Mauget-Fa\u00ffsse","year":"2006","journal-title":"Eur J Ophthalmol"},{"key":"R10-15-20210129","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00006982-200210000-00001","article-title":"Treatment of polypoidal choroidal vasculopathy with photodynamic therapy","volume":"22","author":"Spaide","year":"2002","journal-title":"Retina"},{"key":"R11-15-20210129","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.ophtha.2003.12.056","article-title":"Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: One-year results of a prospective case series","volume":"111","author":"Chan","year":"2004","journal-title":"Ophthalmology"},{"key":"R12-15-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000076844","article-title":"Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula","volume":"218","author":"Lee","year":"2004","journal-title":"Ophthalmologica"},{"key":"R14-15-20210129","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","article-title":"Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan Study","volume":"35","author":"Gomi","year":"2015","journal-title":"Retina"},{"key":"R15-15-20210129","first-page":"937","article-title":"Five-year visual outcomes of typical age-related macular degeneration and\/or polypoidal choroidal vasculopathy patients who received photodynamic therapy (PDT) as initial treatment in comparison with patients prior to the PDT era","volume":"116","author":"Hata","year":"2012","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"R16-15-20210129","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/eye.2013.179","article-title":"Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy","volume":"27","author":"Inoue","year":"2013","journal-title":"Eye (Lond"},{"key":"R17-15-20210129","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/eye.2008.265","article-title":"Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy","volume":"23","author":"Lee","year":"2009","journal-title":"Eye (Lond"},{"key":"R18-15-20210129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10384-013-0245-9","article-title":"Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity","volume":"57","author":"Mori","year":"2013","journal-title":"Jpn J Ophthalmol"},{"key":"R19-15-20210129","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/eye.2011.324","article-title":"Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy","volume":"26","author":"Cho","year":"2012","journal-title":"Eye (Lond"},{"key":"R20-15-20210129","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IAE.0b013e3181f84fdf","article-title":"One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy","volume":"31","author":"Cheng","year":"2011","journal-title":"Retina"},{"key":"R21-15-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12886-015-0026-y","article-title":"Individualized ranibizumab therapy strategies in year 3 after as-needed treatment for polypoidal choroidal vasculopathy","volume":"15","author":"Hikichi","year":"2015","journal-title":"BMC Ophthalmol"},{"key":"R22-15-20210129","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"R23-15-20210129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","article-title":"Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy","volume":"148","author":"Cho","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R24-15-20210129","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/IAE.0b013e31820d3f3f","article-title":"Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy","volume":"31","author":"Lai","year":"2011","journal-title":"Retina"},{"key":"R25-15-20210129","first-page":"2311","article-title":"Profile of conbercept in the treatment of neovascular age-related macular degeneration","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"R26-15-20210129","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","article-title":"Safety and efficacy of conbercept in neovascular age-related macular degeneration: Results from a 12-month randomized phase 2 study: AURORA study","volume":"121","author":"Li","year":"2014","journal-title":"Ophthalmology"},{"key":"R27-15-20210129","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2010.08.008","article-title":"A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration","volume":"118","author":"Zhang","year":"2011","journal-title":"Ophthalmology"},{"key":"R28-15-20210129","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/bjo.2004.049296","article-title":"The origins of polypoidal choroidal vasculopathy","volume":"89","author":"Yuzawa","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R29-15-20210129","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1167\/iovs.08-2134","article-title":"Clinicopathologic findings in polypoidal choroidal vasculopathy","volume":"49","author":"Nakashizuka","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R30-15-20210129","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1111\/aos.12110","article-title":"Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types","volume":"91","author":"Kawamura","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R31-15-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"R32-15-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2415-14-83","article-title":"Associations of complement factor B and complement component 2 genotypes with subtypes of polypoidal choroidal vasculopathy","volume":"14","author":"Tanaka","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"R33-15-20210129","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"R34-15-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.2007.135103","article-title":"Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","volume":"92","author":"Lai","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R35-15-20210129","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R36-15-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ajo.2012.01.010","article-title":"Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment","volume":"154","author":"Yamashiro","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R37-15-20210129","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bjophthalmol-2012-302652","article-title":"Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy","volume":"97","author":"Hikichi","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R38-15-20210129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/IAE.0b013e3182618be0","article-title":"Intravitreal ranibizumab for polypoidal choroidal vasculopathy in non-Asian patients","volume":"33","author":"Marcus","year":"2013","journal-title":"Retina"},{"key":"R39-15-20210129","doi-asserted-by":"crossref","first-page":"136","DOI":"10.4103\/0301-4738.109390","article-title":"Intravitreal bevacizumab monotherapy for treatment-na\u00efve polypoidal choroidal vasculopathy","volume":"61","author":"Chhablani","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"R40-15-20210129","first-page":"343","article-title":"Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab","volume":"8","author":"Yamashita","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"R41-15-20210129","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","article-title":"Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy","volume":"156","author":"Kang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R42-15-20210129","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-014-2707-2","article-title":"Short-term efficacy of intravitreal aflibercept for patients with treatment-na\u00efve polypoidal choroidal vasculopathy","volume":"253","author":"Ijiri","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R43-15-20210129","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1167\/iovs.11-7546","article-title":"Associations of complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotypes with subtypes of polypoidal choroidal vasculopathy","volume":"52","author":"Tanaka","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R44-15-20210129","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0002-9394(02)01404-6","article-title":"Polypoidal choroidal vasculopathy: Natural history","volume":"133","author":"Uyama","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"R45-15-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10384-007-0498-2","article-title":"Incidence and clinical patterns of polypoidal choroidal vasculopathy in Korean patients","volume":"52","author":"Byeon","year":"2008","journal-title":"Jpn J Ophthalmol"},{"key":"R46-15-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/IAE.0b013e318188c839","article-title":"A classification system for polypoidal choroidal vasculopathy","volume":"29","author":"Cackett","year":"2009","journal-title":"Retina"},{"key":"R47-15-20210129","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/bjophthalmol-2014-305059","article-title":"A novel classification of the vascular patterns of polypoidal choroidal vasculopathy and its relation to clinical outcomes","volume":"98","author":"Tan","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R48-15-20210129","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.preteyeres.2005.01.001","article-title":"Polypoidal choroidal vasculopathy: Angiographic characterization of the network vascular elements and a new treatment paradigm","volume":"24","author":"Costa","year":"2005","journal-title":"Prog Retin Eye Res"},{"key":"R49-15-20210129","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/archopht.1992.01080180099035","article-title":"Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration","volume":"110","author":"Bressler","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R50-15-20210129","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/00006982-199414020-00004","article-title":"Clinicopathologic correlation of choroidal neovascularization demonstrated by indocyanine green angiography in a patient with retention of good vision for almost four years","volume":"14","author":"Chang","year":"1994","journal-title":"Retina"},{"key":"R51-15-20210129","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/bjo.86.10.1093","article-title":"Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study","volume":"86","author":"Okubo","year":"2002","journal-title":"Br J Ophthalmol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/0366-6999.192779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:41:17Z","timestamp":1623958877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00029330-201611050-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,5]]},"references-count":50,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0366-6999.192779","relation":{},"ISSN":["0366-6999"],"issn-type":[{"value":"0366-6999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,5]]}}}